Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study.

Magnus T DillonLorna GroveKate L NewboldHeather ShawNicholas F BrownJeanne MendellShuquan ChenRobert A BeckmanAnne JenningsMarivic RicamaraJonathan GreenbergMartin ForsterKevin J Harrington

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Patritumab (18 mg/kg loading dose, 9 mg/kg maintenance dose) plus cetuximab/platinum was tolerable, active in SCCHN, and selected as the phase II dose regimen.

Keyphrases

squamous cell carcinoma
phase ii
clinical trial
locally advanced
open label
small cell lung cancer
metastatic colorectal cancer
randomized controlled trial
stem cells
lymph node metastasis
mesenchymal stem cells
cell therapy
smoking cessation